Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 5,324,144 9.985% | 736,110 (+16.04%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | ASLAN Pharmaceuticals Limited ASLN | K2 HealthVentures Equity Trust LLC | 61,535,383 9.990% | 58,726,924 (+2091.07%) | Filing History |
| 2024-11-14 4:05 pm Sale | 2024-09-30 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | K2 HealthVentures Equity Trust LLC | 2,873 0.020% | -339,240 (-99.16%) | Filing History |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 4,588,034 9.985% | 2,488,225 (+118.50%) | Filing History |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | Elevation Oncology, Inc. ELEV | K2 HealthVentures Equity Trust LLC | 1,784,169 4.000% | 217,705 (+13.90%) | Filing History |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | Molecular Templates, Inc. MTEM | K2 HealthVentures Equity Trust LLC | 596,145 9.985% | 596,145 (New Position) | Filing History |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | ASLAN Pharmaceuticals Limited ASLN | K2 HealthVentures Equity Trust LLC | 2,808,459 5.200% | 2,808,459 (New Position) | Filing History |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | K2 HealthVentures Equity Trust LLC | 342,113 7.500% | 342,113 (New Position) | Filing History |
| 2024-02-14 4:41 pm Purchase | 2022-10-25 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | K2 HealthVentures Equity Trust LLC | 10,524,401 7.800% | 10,524,401 (New Position) | Filing History |
| 2023-06-26 5:27 pm Purchase | 2023-06-16 | 13G | Molecular Templates, Inc. MTEM | K2 HealthVentures Equity Trust LLC | 416,724 9.985% | 416,724 (New Position) | Filing History |
| 2023-03-20 5:20 pm Purchase | 2023-02-24 | 13G | ASLAN Pharmaceuticals Limited ASLN | K2 HealthVentures Equity Trust LLC | 3,308,266 6.200% | 3,308,266 (New Position) | Filing History |
| 2022-11-01 4:06 pm Purchase | 2022-04-01 | 13G | Oncorus, Inc. ONCR | K2 HealthVentures Equity Trust LLC | 2,593,767 9.100% | 2,593,767 (New Position) | Filing History |
| 2022-09-30 5:24 pm Purchase | 2022-07-27 | 13G | Elevation Oncology, Inc. ELEV | K2 HealthVentures Equity Trust LLC | 1,566,464 6.300% | 1,566,464 (New Position) | Filing History |
| 2022-09-30 5:21 pm Purchase | 2022-09-09 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 2,099,809 9.985% | 2,099,809 (New Position) | Filing History |